Stockpolly
Search
KOD · NASDAQ · Biotechnology

Kodiak Sciences (KOD)

Develops intravitreal biologics for retinal vascular and inflammatory diseases.

$37.75
Pre-market+0.24 (+0.64%)
At close$37.51(+1.21%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue777777000000
Gross profit−7−7−7−7−7−7000000
485739414039595662576067
Research & development364730333232444350454956
11109988141312121111
Selling & marketing0−70000000000
General & administrative0170000141312121111
Other expenses000000200000
Operating income−55−63−46−48−47−46−59−56−62−57−60−67
443332211121
Interest income543332211121
Interest expense000000000000
Other non-operating income−4−4−3−3−3−2−2−1−1−4−20
Income before tax−50−60−43−45−44−44−57−54−61−57−58−66
Net income from continuing operations−50−60−43−45−44−44−57−54−61−57−58−66
Net income−50−60−43−45−44−44−57−54−61−57−58−66
EPS, basic−$0.95−$1.13−$0.82−$0.86−$0.84−$0.84−$1.09−$1.03−$1.16−$1.04−$0.94−$1.05
EPS, diluted−$0.95−$1.13−$0.82−$0.86−$0.84−$0.84−$1.09−$1.03−$1.16−$1.04−$0.94−$1.05
Weighted average shares, basic525253535353535353536263
Weighted average shares, diluted525253535353535353536263
EBITDA−43−53−36−38−37−37−51−48−55−47−52−67
Depreciation & amortization777777777760
EBIT−50−60−43−45−44−44−57−54−61−53−58−67